Eukarÿs is pleased to announce the strengthening of its Board of Directors alongside the appointment of Guillaume Prunier as CEO. Gabriel Festoc, PhD, former President of Polyplus (acquired by Sartorius in 2023 for €2.4 billion), is a leading expert in bioproduction technologies, particularly in cell & gene therapy. Anne Lauvergeon, representing ALP, brings her industrial and financial expertise. Formerly Managing Partner at Lazard and CEO of Areva, she is a strong advocate of innovation. These strategic appointments will help Eukarÿs leverage its cutting-edge C3P3® technology to revolutionize the biomanufacturing industry.